Skip to content
2000
image of Novel Drug Delivery Systems Approved by USFDA from 2019 to 2023: A Comprehensive Review

Abstract

In recent years, tremendous progress in the field of novel drug delivery systems (NDDS), which has prompted the creation of new strategies to enhance treatment results and patient compliance. The goal of this comprehensive review is to provide a summary of the NDDS that the US Food and Drug Administration (USFDA) has approved from 2019 to 2023. Various databases, including PubMed, Scopus, USFDA, and patent websites were utilized to gather relevant information. The selected NDDSs were categorized based on their delivery route, such as oral, injectable, transdermal, pulmonary, nasal, ocular, and implantable. For each delivery route, the review provides a detailed analysis of the approved NDDSs, including their mechanisms of action, advantages, limitations, and clinical applications. Additionally, the review discusses the challenges faced during the development and commercialization of these systems, as well as the prospects and potential areas of improvement. The findings of this comprehensive review demonstrate the remarkable progress made in the field of NDDSs, with the USFDA approving several innovative technologies in recent years. The approved NDDSs have shown promising results in enhancing drug stability, bioavailability, and controlled release, leading to improved therapeutic outcomes and patient convenience. In conclusion, this comprehensive review provides a valuable resource for researchers, healthcare professionals, and pharmaceutical industries, offering insights into the latest advancements in NDDSs approved by the US FDA. The knowledge gained from this review can guide future research endeavors, foster innovation, and contribute to developing more effective and patient-friendly NDDS strategies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdd/10.2174/0115672018353367250317063449
2025-09-01
2025-09-03

  • From This Site

    /content/journals/cdd/10.2174/0115672018353367250317063449
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Tiwari G. Tiwari R. Bannerjee S.K. Bhati L. Pandey S. Pandey P. Sriwastawa B. Drug delivery systems: An updated review. Int. J. Pharm. Investig. 2012 2 1 2 11 10.4103/2230‑973X.96920 23071954
    [Google Scholar]
  2. Gilero. Drug delivery systems-What is drug delivery & more. 2023 Available from: https://www.gilero.com/news/drug-delivery-overview (Accessed on: 24 Oct 2023).
  3. Drug delivery systems. National Institute of Biomedical Imaging and Bioengineering. 2023 Available from: https://www.nibib.nih.gov/science-education/science-topics/drug-delivery-systems-getting-drugs-their-targets-controlled-manner (Accessed on: 24 Oct 2023).
  4. Gao J. Karp J.M. Langer R. Joshi N. The future of drug delivery. Chem. Mater. 2023 35 2 359 363 10.1021/acs.chemmater.2c03003 37799624
    [Google Scholar]
  5. Vargason A.M. Anselmo A.C. Mitragotri S. The evolution of commercial drug delivery technologies. Nat. Biomed. Eng. 2021 5 9 951 967 10.1038/s41551‑021‑00698‑w 33795852
    [Google Scholar]
  6. FDA. Commissioner O of the FDA. The drug development process. 2023 Available from: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process (Accessed on: 24 Oct 2023).
  7. FDA. Learn about drug and device approvals. 2023 Available from: https://www.fda.gov/patients/learn-about-drug-and-device-approvals (Accessed on: 24 Oct 2023).
  8. FDA. Research C for DE and FDA’s drug review process: Continued. 2023 Available from: https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-continued (Accessed on: 24 Oct 2023).
  9. FDA. Research C for DE and FDA’s development and approval process of drugs. 2023 Available from: https://www.fda.gov/drugs/development-approval-process-drugs (Accessed on: 24 Oct 2023).
  10. FDA. Drug approval process. Drug sponsor’s discovery and screening phase. 2023 Available from: https://www.fda.gov/media/82381/download (Accessed on: 24 Oct 2023).
  11. FDA. The device development process. 2023 Available from: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/device-development-process (Accessed on: 25 Oct 2023).
  12. ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful progression-free survival and overall survival across multiple HER2-expressing advanced solid tumors in DESTINY-PanTumor02 Phase II trial. 2023 Available from: https://www.astrazeneca-us.com/media/press-releases/2023/enhertu-fam-trastuzumab-deruxtecan-nxki-demonstrated-clinically-meaningful-progression-free-survival-and-overall-survival-across-multiple-her2-expressing-advanced-solid-tumors-in-destiny-pantumor02-phase-ii-trial-07272023.html (Accessed on: 25 Oct 2023).
  13. ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful survival across multiple HER2-expressing advanced solid tumors in DESTINY-PanTumor02 Phase II trial. 2023 Available from: https://www.astrazeneca-us.com/media/press-releases/2023/enhertu-fam-trastuzumab-deruxtecan-nxki-demonstrated-clinically-meaningful-survival-across-multiple-her2-expressing-advanced-solid-tumors-in-destiny-pantumor02-phase-ii-trial.html (Accessed on: 25 Oct 2023).
  14. ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer. 2023 Available from: https://www.businesswire.com/news/home/20220805005482/en/ENHERTU%C2%AE-fam-trastuzumab-deruxtecan-nxki-approved-in-the-US-as-the-first-HER2-directed-therapy-for-patients-with-HER2-low-metastatic-breast-cancer (Accessed on: 25 Oct 2023).
  15. Highlights of prescription information. NAYZILAM® (midazolam) nasal spray, CIV. 2023 Available from: https://www.ucb-usa.com/nayzilam-prescribing-information.pdf (Accessed on: 25 Oct 2023).
  16. UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S. 2023 Available from: https://www.ucb.com/stories-media/Press-Releases/article/UCB-announces-NAYZILAM-midazolam-nasal-spray-now-approved-by-FDA-to-treat-intermittent-stereotypic-episodes-of-frequent-seizure-activity-in-people-living-with-epilepsy-in-the-U-S (Accessed on: 25 Oct 2023).
  17. DailyMed - NAYZILAM- midazolam spray. 2023 Available from: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2b29422e-54d5-4a49-8522-e9cf752368c3 (Accessed on: 25 Oct 2023).
  18. Sarfraz N. Okuampa D. Hansen H. Alvarez M. Cornett E.M. Kakazu J. Kaye A.M. Kaye A.D. pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Health Psychol. Res. 2022 10 2 34222 10.52965/001c.34222 35774905
    [Google Scholar]
  19. FDA approves expanded use of Wakix for narcolepsy. Sleep medicine. American Academy of Sleep Medicine – Association for Sleep Clinicians and Researchers. 2023 Available from: https://aasm.org/fda-approves-expanded-use-of-wakix-for-narcolepsy (Accessed on: 25 Oct 2023).
  20. Mechanism of Action | WAKIX® (pitolisant) HCP site. 2023 Available from: https://wakixhcp.com (Accessed on: 25 Oct 2023).
  21. Guevarra J.T. Hiensch R. Varga A.W. Rapoport D.M. Pitolisant to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy: Rationale and clinical utility. Nat. Sci. Sleep 2020 12 709 719 10.2147/NSS.S264140 33117007
    [Google Scholar]
  22. Medscape. FDA okays pitolisant (Wakix) for narcolepsy. 2023 Available from: https://www.medscape.com/viewarticle/916895 (Accessed on: 25 Oct 2023).
  23. Treat postpartum depression. ZULRESSO® (brexanolone) CIV. 2023 Available from: https://www.zulresso.com (Accessed on: 25 Oct 2023).
  24. Edinoff A.N. Odisho A.S. Lewis K. Kaskas A. Hunt G. Cornett E.M. Kaye A.D. Kaye A. Morgan J. Barrilleaux P.S. Lewis D. Viswanath O. Urits I. Brexanolone, a GABAA modulator, in the treatment of postpartum depression in adults: A comprehensive review. Front. Psychiatry 2021 12 699740 10.3389/fpsyt.2021.699740 34594247
    [Google Scholar]
  25. Zulresso (Brexanolone): New drug for postpartum depression. 2023 Available from: https://www.psycom.net/mental-health-medications/brexanalone (Accessed on: 25 Oct 2023).
  26. Scarff J.R. Use of brexanolone for postpartum depression. Innov. Clin. Neurosci. 2019 16 11-12 32 35 32082941
    [Google Scholar]
  27. Cornett E.M. Rando L. Labbé A.M. Perkins W. Kaye A.M. Kaye A.D. Viswanath O. Urits I. Brexanolone to treat postpartum depression in adult women. Psychopharmacol. Bull. 2021 51 2 115 130 34092826
    [Google Scholar]
  28. MGH center for women’s mental health. A primer on brexanolone (Zulresso) for postpartum depression. 2023 Available from: https://womensmentalhealth.org/posts/a-primer-on-brexanolone-zulresso-for-postpartum-depression (Accessed on: 25 Oct 2023).
  29. GivlaariTM (givosiran) for the treatment of acute hepatic porphyria. 2023 Available from: https://www.clinicaltrialsarena.com/projects/givlaari-givosiran (Accessed on: 25 Oct 2023).
  30. Givosiran-an overview, 2023 Available from: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/givosiran (Accessed on: 25 Oct 2023).
  31. GIVLAARI HCP. What is GIVLAARI® (givosiran)? 2023 Available from: https://www.givlaarihcp.com/how-givlaari-works (Accessed on: 25 Oct 2023).
  32. Givlaari (givosiran). CenterWatch. 2023 Available from: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4565-givlaari-givosiran (Accessed on: 25 Oct 2023).
  33. Highlights of prescription information. GIVLAARI (giosiran) injection, for subcutaneous use. 2023 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf (Accessed on: 25 Oct 2023).
  34. Pipeline–Enfortumab Vedotin (PADCEV)–Seagen. 2023 Available from: https://www.seagen.com/science/pipeline/enfortumab-vedotin (Accessed on: 25 Oct 2023).
  35. PADCEV® (enfortumab vedotin-ejfv). About PADCEV®. 2023 Available from: https://www.padcev.com/about-padcev (Accessed on: 25 Oct 2023).
  36. PADCEV. PADCEV (enfortumab vedotin-ejfv). Official patient site. 2023 Available from: https://www.padcev.com (Accessed on: 25 Oct 2023).
  37. FDA. Commissioner O of the FDA. FDA approves new type of therapy to treat advanced urothelial cancer. 2023 Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-type-therapy-treat-advanced-urothelial-cancer (Accessed on: 25 Oct 2023).
  38. Wong J.L. Rosenberg J.E. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. Expert Opin. Biol. Ther. 2021 21 7 863 873 10.1080/14712598.2021.1929168 34030536
    [Google Scholar]
  39. Deeks E.D. Polatuzumab vedotin: First global approval. Drugs 2019 79 13 1467 1475 10.1007/s40265‑019‑01175‑0 31352604
    [Google Scholar]
  40. Polivy (polatuzumab vedotin-piiq). CenterWatch. 2023 Available from: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4015-polivy-polatuzumab-vedotin-piiq (Accessed on: 25 Oct 2023).
  41. Genentech: Press releases. 2023 Available from: https://www.gene.com/media/press-releases/14965/2022-08-15/fda-accepts-supplemental-biologics-licen (Accessed on: 25 Oct 2023).
  42. CHMP recommends conditional EU approval of Roche’s Polivy for people with previously treated aggressive lymphoma. 2023 Available from: https://www.roche.com/de/investors/updates/inv-update-2019-11-15 (Accessed on: 25 Oct 2023).
  43. Drugs.com. Polivy (polatuzumab vedotin-piiq) FDA approval history. 2023 Available from: https://www.drugs.com/history/polivy.html (Accessed on: 25 Oct 2023).
  44. Contraceptive patch. Twirla®. 2023 Available from: https://www.twirla.com/hcp (Accessed on: 25 Oct 2023).
  45. Levonorgestrel and ethinyl estradiol transdermal system. 2023 Available from: https://afaxyspharma.com/products/contraceptive-patch/twirla (Accessed on: 25 Oct 2023).
  46. Twirla transdermal: Uses, side effects, interactions, pictures, warnings & dosing. 2023 Available from: https://www.webmd.com/drugs/2/drug-179630/twirla-transdermal/details (Accessed on: 25 Oct 2023).
  47. Twirla patch: Usage, side effects, warnings. 2023 Available from: https://www.drugs.com/twirla.html (Accessed on: 25 Oct 2023).
  48. Lassiter G. Bergeron C. Guedry R. Cucarola J. Kaye A.M. Cornett E.M. Kaye A.D. Varrassi G. Viswanath O. Urits I. Belantamab mafodotin to treat multiple myeloma: A comprehensive review of disease, drug efficacy and side effects. Curr. Oncol. 2021 28 1 640 660 10.3390/curroncol28010063 33494319
    [Google Scholar]
  49. Belantamab mafodotin. 2023 Available from: https://en.wikipedia.org/w/index.php?title=Belantamab_mafodotin&oldid=1142960326 (Accessed on: 25 Oct 2023).
  50. Blenrep (belantamab mafodotin-blmf). 2023 Available from: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4642-blenrep-belantamab-mafodotin-blmf (Accessed on: 25 Oct 2023).
  51. Background information for blenrep belantamab mafodotin. 2023 Available from: https://us.gsk.com/media/6072/background-information-for-blenrep-belantamab-mafodotin-blmf.pdf (Accessed on: 25 Oct 2023).
  52. Belantamab mafodotin (Blenrep). 2023 Available from: https://hemonc.org/wiki/Belantamab_mafodotin_(Blenrep) (Accessed on: 25 Oct 2023).
  53. Stenger M. Tafasitamab-cxix in the treatment of diffuse large B-cell lymphoma-The ASCO post. 2023 Available from: https://ascopost.com/issues/august-25-2020/tafasitamab-cxix-in-the-treatment-of-diffuse-large-b-cell-lymphoma (Accessed on: 25 Oct 2023).
  54. MONJUVI® (tafasitamab-cxix) 200 mg: Treatment for R/R DLBCL. 2023 Available from: https://www.monjuvi.com/about-monjuvi (Accessed on: 25 Oct 2023).
  55. MONJUVI® (tafasitamab-cxix) MOA. 2023 Available from: https://www.monjuvihcp.com/moa (Accessed on: 25 Oct 2023).
  56. Monjuvi (tafasitamab-cxix). 2023 Available from: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4641-monjuvi-tafasitamab-cxix (Accessed on: 25 Oct 2023).
  57. Highlights of prescription information. Monjuvi® (tafasitamab-cxix) for injection for intravenous use. 2023 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761163s000lbl.pdf (Accessed on: 25 Oct 2023).
  58. Qelbree (viloxazine extended-release capsules). 2023 Available from: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4698-qelbree-viloxazine-extended-release-capsules (Accessed on: 25 Oct 2023).
  59. DailyMed-QELBREE-viloxazine hydrochloride capsule, extended release. 2023 Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aedf408d-0f84-418d-9416-7c39ddb0d29a (Accessed on: 25 Oct 2023).
  60. What is Qelbree® (viloxazine extended-release capsules). 2023 Available from: https://www.qelbree.com/adults/qelbree-for-adhd (Accessed on: 25 Oct 2023).
  61. Qelbree’s delivery system. 2023 Available from: https://www.hmpgloballearningnetwork.com/site/pcn/addressing-unmet-needs-in-attention-deficit/hyperactivity-disorder-in-adults (Accessed on: 25 Oct 2023).
  62. Supernus announces FDA approval of QelbreeTM (SPN-812) for the treatment of ADHD-Supernus Pharmaceuticals. 2023 Available from: https://ir.supernus.com/news-releases/news-release-details/supernus-announces-fda-approval-qelbreetm-spn-812-treatment-adhd (Accessed on: 25 Oct 2023).
  63. RYBREVANT (amivantamab-vmjw) for the treatment of non-small cell lung cancer. Clinical trials arena. 2023 Available from: https://www.clinicaltrialsarena.com/projects/rybrevant-nsclc (Accessed on: 25 Oct 2023).
  64. RYBREVANT® (amivantamab-vmjw). 2023 Available from: https://www.rybrevanthcp.com (Accessed on: 25 Oct 2023).
  65. Johnson JPC of J & RYBREVANTTM (amivantamab-vmjw) receives FDA approval as the first targeted treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. 2023 Available from: https://www.prnewswire.com/news-releases/rybrevant-amivantamab-vmjw-receives-fda-approval-as-the-first-targeted-treatment-for-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-301297080.html (Accessed on: 25 Oct 2023).
  66. U.S. FDA approves TICOVACTM, Pfizer’s Tick-Borne Encephalitis (TBE) vaccine. 2023 Available from: https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-ticovactm-pfizers-tick-borne-encephalitis (Accessed on: 25 Oct 2023).
  67. TicoVacTM (Tick-Borne Encephalitis Vaccine). Safety info. 2023 Available from: https://www.ticovac.com (Accessed on: 25 Oct 2023).
  68. TicoVac (Tick-Borne Encephalitis vaccine suspension for intramuscular injection): Uses, dosage, side effects, interactions, warning. 2023 Available from: https://www.rxlist.com/ticovac-drug.htm (Accessed on: 25 Oct 2023).
  69. Highlights of prescription information. TicoVac (Tick-Borne Encephalitis vaccine), suspension for intramuscular injection. 2023 Available from: https://www.fda.gov/media/151502/download (Accessed on: 25 Oct 2023).
  70. Aducanumab. 2023 Available from: https://en.wikipedia.org/w/index.php?title=Aducanumab&oldid=1181528769 (Accessed on: 25 Oct 2023).
  71. ADUHELM (aducanumab-avwa) for the treatment of Alzheimer’s disease. Clinical trials arena. 2023 Available from: https://www.clinicaltrialsarena.com/projects/aduhelm-aducanumab-avwa-alzheimers (Accessed on: 25 Oct 2023).
  72. Aduhelm (aducanumab-avwa). 2023 Available from: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4716-aduhelm-aducanumab-avwa (Accessed on: 25 Oct 2023).
  73. Haddad H.W. Malone G.W. Comardelle N.J. Degueure A.E. Kaye A.M. Kaye A.D. Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s disease: A comprehensive review. Health Psychol. Res. 2022 10 1 31925 10.52965/001c.31925 35928986
    [Google Scholar]
  74. Amondys 45 (Casimersen injection): Uses, dosage, side effects, interactions, warning. 2023 Available from: https://www.rxlist.com/amondys-45-drug.htm (Accessed on: 25 Oct 2023).
  75. Amondys 45 (casimersen) dosing, indications, interactions, adverse effects, and more. 2023 Available from: https://reference.medscape.com/drug/amondys-45-casimersen-4000136 (Accessed on: 25 Oct 2023).
  76. Amondys 45 (casimersen). 2023 Available from: https://dss.mo.gov/mhd/cs/advisory/rdac/pdf/amondys-45-casimersen-ndfb_mo.pdf (Accessed on: 25 Oct 2023).
  77. Highlights of prescription information. AMONDYS 45 (casimersen) injection, for intravenous use. 2023 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213026lbl.pdf (Accessed on: 25 Oct 2023).
  78. Amondys 45 (Casimersen) for the treatment of Duchenne muscular dystrophy. Clinical trials arena. 2023 Available from: https://www.clinicaltrialsarena.com/projects/amondys-45-casimersen-dmd-treatment (Accessed on: 25 Oct 2023).
  79. Bristol Myers Squibb receives European commission approval for CAR T cell therapy Breyanzi (lisocabtagene maraleucel) for relapsed or refractory large B-cell lymphoma after one prior therapy. 2023 Available from: https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-CAR-T-Cell-Therapy-Breyanzi-lisocabtagene-maraleucel-for-Relapsed-or-Refractory-Large-B-cell-Lymphoma-After-One-Prior-Therapy/default.aspx (Accessed on: 25 Oct 2023).
  80. Breyanzi (lisocabtagene maraleucel) for the treatment of large B-cell lymphoma (LBCL), USA. Clinical trials arena. 2023 Available from: https://www.clinicaltrialsarena.com/projects/breyanzi-for-the-treatment-of-large-b-cell-lymphoma-lbcl (Accessed on: 25 Oct 2023).
  81. Research C for BE and BREYANZI (lisocabtagene maraleucel). 2023 Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel (Accessed on: 25 Oct 2023).
  82. EMA. European medicines agency. Breyanzi. 2023 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/breyanzi (Accessed on: 25 Oct 2023).
  83. Breyanzi® (lisocabtagene maraleucel) CAR T cell therapy treatment for large B-cell lymphoma (LBCL). 2023 Available from: https://www.breyanzi.com (Accessed on: 25 Oct 2023).
  84. Breyanzi CAR T cell therapy for healthcare providers. 2023 Available from: https://www.breyanzihcp.com (Accessed on: 25 Oct 2023).
  85. Adbry (Tralokinumab-ldrm). National Eczema Association. 2023 Available from: https://nationaleczema.org/tralokinumab-faq (Accessed on: 25 Oct 2023).
  86. Leopharma. About Adbry. 2023 Available from: https://www.adbryhcp.com/about-adbry (Accessed on: 25 Oct 2023).
  87. Tralokinumab. 2023 Available from: https://go.drugbank.com/drugs/DB12169 (Accessed on: 25 Oct 2023).
  88. Tralokinumab. 2023 Available from: https://en.wikipedia.org/w/index.php?title=Tralokinumab&oldid=1152518932 (Accessed on: 25 Oct 2023).
  89. DailyMed-ADBRY-tralokinumab-ldrm injection, solution. 2023 Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8020b69-3001-44e2-9b5d-5f93d9aaf6e1 (Accessed on: 25 Oct 2023).
  90. A treatment option. CABENUVA (cabotegravir; rilpivirine). 2023 Available from: https://www.cabenuva.com (Accessed on: 25 Oct 2023).
  91. ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment. 2023 Available from: https://viivhealthcare.com/en-us/media-center/news/press-releases/2021/january/viiv-healthcare-announces-fda-approval-of-cabenuva--cabotegravir (Accessed on: 25 Oct 2023).
  92. CABENUVA-VOCABRIA. 2023 Available from: https://viivhealthcare.com/content/dam/cf-viiv/viiv-healthcare/en_GB/medicines/CABENUVA-VOCABRIA-PM-26-Mar-2021.pdf (Accessed on: 25 Oct 2023).
  93. ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment. 2023 Available from: https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2022/january/viiv-healthcare-announces-fda-approval-of-cabenuva-for-use-every-two-months (Accessed on: 25 Oct 2023).
  94. CABENUVA cabotegravir prolonged-release suspension for injection and rilpivirine prolonged-release suspension for injection. 2023 Available from: https://viivhealthcare.com/content/dam/cf-viiv/viiv-healthcare/en_AU/documents/cabenua-pi-001-approved.pdf (Accessed on: 25 Oct 2023).
  95. NexoBrid for Eschar removal in thermal burns. 2023 Available from: https://www.drugtopics.com/view/nexobrid-for-eschar-removal-in-thermal-burns (Accessed on: 25 Oct 2023).
  96. Highlights of prescription information. NexoBrid® (anacaulase-bcdb) for topical gel. 2023 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761192s000lbl.pdf (Accessed on: 25 Oct 2023).
  97. NexoBrid® (anacaulase-bcdb). Enzymatic eschar removal. 2023 Available from: https://www.nexobrid-us.com (Accessed on: 25 Oct 2023).
  98. Anacaulase monograph for professionals. 2023 Available from: https://www.drugs.com/monograph/anacaulase.html (Accessed on: 25 Oct 2023).
  99. Highlights of prescription information. XENOVIEW (Xenon Xe 129 hyperpolarized), for inhalation. 2023 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214375s000lbl.pdf (Accessed on: 25 Oct 2023).
  100. Xenon Xe 129 hyperpolarized (inhalation route) description and brand names. 2023 Available from: https://www.mayoclinic.org/drugs-supplements/xenon-xe-129-hyperpolarized-inhalation-route/description/drg-20543669 (Accessed on: 25 Oct 2023).
  101. Xenoview. Hyperpolarized Xe 129 Gas-Xenoview. 2023 Available from: https://xenoview.net/about-xenoview/hyperpolarized-xe-129-gas (Accessed on: 25 Oct 2023).
  102. Xenon Xe-129. 2023 Available from: https://go.drugbank.com/drugs/DB17386 (Accessed on: 25 Oct 2023).
  103. LUNSUMIOTM (mosunetuzumab-axgb) for third-line or later follicular lymphoma. 2023 Available from: https://www.lunsumio.com (Accessed on: 25 Oct 2023).
  104. Genentech: Press releases. 2023 Available from: https://www.gene.com/media/press-releases/14978/2022-12-22/fda-approves-genentechs-lunsumio-a-first (Accessed on: 25 Oct 2023).
  105. Norman M. A novel therapeutic option for the management of R/R FL. Pharm. Times 2023 5 3
    [Google Scholar]
  106. Highlights of prescription information. LUNSUMIOTM (mosunetuzumab-axgb) injection, for intravenous use. 2023 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf (Accessed on: 25 Oct 2023).
  107. How LUNSUMIOTM (mosunetuzumab-axgb) is thought to work. 2023 Available from: https://www.lunsumio-hcp.com/about/how-lunsumio-works.html (Accessed on: 25 Oct 2023).
  108. Gilead announces first global regulatory approval of Sunlenca® (Lenacapavir), the only twice-yearly HIV treatment option. 2023 Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2022/8/gilead-announces-first-global-regulatory-approval-of-sunlenca-lenacapavir-the-only-twiceyearly-hiv-treatment-option (Accessed on: 25 Oct 2023).
  109. Paik J. Lenacapavir: First approval. Drugs 2022 82 14 1499 1504 10.1007/s40265‑022‑01786‑0 36272024
    [Google Scholar]
  110. Sunlenca® (lenacapavir) receives FDA approval as a first-in-class, twice-yearly treatment option for people living with multi-drug resistant HIV. 2023 Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/sunlenca-lenacapavir-receives-fda-approval-as-a-firstinclass-twiceyearly-treatment-option-for-people-living-with-multidrug-resistant-hiv (Accessed on: 25 Oct 2023).
  111. Gilead Sciences announces new clinical trial in Europe to assess lenacapavir for HIV prevention as part of landmark purpose program. 2023 Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2023/10/gilead-sciences-announces-new-clinical-trial-in-europe-to-assess-lenacapavir-for-hiv-prevention-as-part-of-landmark-purpose-program (Accessed on: 25 Oct 2023).
  112. Dzinamarira T. Almehmadi M. Alsaiari A.A. Allahyani M. Aljuaid A. Alsharif A. Khan A. Kamal M. Rabaan A.A. Alfaraj A.H. AlShehail B.M. Alotaibi N. AlShehail S.M. Imran M. Highlights on the development, related patents, and prospects of lenacapavir: The first-in-class HIV-1 capsid inhibitor for the treatment of multi-drug-resistant HIV-1 infection. Medicina (Kaunas) 2023 59 6 1041 10.3390/medicina59061041 37374245
    [Google Scholar]
  113. Ublituximab. 2023 Available from: https://en.wikipedia.org/w/index.php?title=Ublituximab&oldid=1165276919 (Accessed on: 25 Oct 2023).
  114. Briumvi (ublituximab-xiiy) for the treatment of multiple sclerosis, USA. Clinical trials arena. 2023 Available from: https://www.clinicaltrialsarena.com/projects/briumvi-ublituximab-xiiy (Accessed on: 25 Oct 2023).
  115. Ublituximab. TG Therapeutics. 2023 Available from: https://www.tgtherapeutics.com/our-pipeline/ublituximab (Accessed on: 25 Oct 2023).
  116. TG Therapeutics announces FDA approval of BRIUMVITM (ublituximab-xiiy). 2023 Available from: https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-fda-approval-briumvitm-ublituximab (Accessed on: 25 Oct 2023).
  117. Lee A. Ublituximab: First approval. Drugs 2023 83 5 455 459 10.1007/s40265‑023‑01854‑z 36920653
    [Google Scholar]
  118. Lecanemab. 2023 Available from: https://en.wikipedia.org/w/index.php?title=Lecanemab&oldid=1181375634 (Accessed on: 25 Oct 2023).
  119. Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease, USA. Clinical trials arena. 2023 Available from: https://www.clinicaltrialsarena.com/projects/leqembi-alzheimers-disease (Accessed on: 25 Oct 2023).
  120. Lecanemab. 2023 Available from: https://go.drugbank.com/drugs/DB14580 (Accessed on: 25 Oct 2023).
  121. DailyMed-LEQEMBI-lecanemab injection, solution. 2023 Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d1ff786-e577-410a-a273-c4d7d0e4e975 (Accessed on: 25 Oct 2023).
  122. Bexagliflozin. 2023 Available from: https://en.wikipedia.org/w/index.php?title=Bexagliflozin&oldid=1175971898 (Accessed on: 25 Oct 2023).
  123. Bahadori S. Bexagliflozin (Brenzavvy): Advancing diabetes management with SGLT-2 inhibition. Pharm. Times 2023 5 4
    [Google Scholar]
  124. DailyMed-BRENZAVVY-bexagliflozin tablet. 2023 Available from: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3cdf28fc-4194-4ad6-aa03-c9eaa68da83e (Accessed on: 25 Oct 2023).
  125. Bexagliflozin. 2023 Available from: https://go.drugbank.com/drugs/DB12236 (Accessed on: 25 Oct 2023).
  126. Brenzavvy (bexagliflozin). 2023 Available from: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4834-brenzavvy-bexagliflozin (Accessed on: 25 Oct 2023).
  127. Jaypirca (pirtobrutinib) for the treatment of relapsed or refractory mantle cell lymphoma, USA. Clinical trials arena. 2023 Available from: https://www.clinicaltrialsarena.com/projects/jaypirca-pirtobrutinib-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma-usa (Accessed on: 25 Oct 2023).
  128. Pirtobrutinib (Jaypirca)-A hematology oncology wiki. 2023 Available from: https://hemonc.org/wiki/Pirtobrutinib_(Jaypirca) (Accessed on: 25 Oct 2023).
  129. Wang M.L. Jurczak W. Zinzani P.L. Eyre T.A. Cheah C.Y. Ujjani C.S. Koh Y. Izutsu K. Gerson J.N. Flinn I. Tessoulin B. Alencar A.J. Ma S. Lewis D. Lech-Maranda E. Rhodes J. Patel K. Maddocks K. Lamanna N. Wang Y. Tam C.S. Munir T. Nagai H. Hernandez-Ilizaliturri F. Kumar A. Fenske T.S. Seymour J.F. Zelenetz A.D. Nair B. Tsai D.E. Balbas M. Walgren R.A. Abada P. Wang C. Zhao J. Mato A.R. Shah N.N. Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J. Clin. Oncol. 2023 41 24 3988 3997 10.1200/JCO.23.00562 37192437
    [Google Scholar]
  130. News-Jaypirca (pirtobrutinib)-LARVOL VERI. 2023 Available from: https://veri.larvol.com/news/loxo-305/drug (Accessed on: 25 Oct 2023).
  131. BTK inhibitor molecule overview. Loxo Oncology. 2023 Available from: https://www.lillyloxooncologypipeline.com/molecule/btk-inhibitor (Accessed on: 25 Oct 2023).
  132. Park B. Orserdu approved for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer. 2023 Available from: https://www.empr.com/home/news/orserdu-approved-for-er-her2-esr1-mutated-advanced-or-metastatic-breast-cancer (Accessed on: 25 Oct 2023).
  133. Stemline Therapeutics Inc. metastatic breast cancer. 2023 Available from: https://radiuspharm.com/stemline-therapeutics-inc-receives-approval-from-u-s-fda-for-orserdutm-elacestrant-as-the-first-and-only-treatment-specifically-indicated-for-patients-with-esr1-mutations-in-er-her2-advanced-or (Accessed on: 25 Oct 2023).
  134. Elacestrant. 2023 Available from: https://go.drugbank.com/drugs/DB06374 (Accessed on: 25 Oct 2023).
  135. European Commission approves Menarini Group’s ORSERDU® (Elacestrant) for the treatment of patients with ER+, HER2- locally advanced or metastatic breast cancer with an activating ESR1 mutation. 2023 Available from: https://www.prnewswire.com/in/news-releases/european-commission-approves-menarini-groups-orserdu-elacestrant-for-the-treatment-of-patients-with-er-her2--locally-advanced-or-metastatic-breast-cancer-with-an-activating-esr1-mutation-301933626.html (Accessed on: 25 Oct 2023).
  136. ER+/HER2- ESR1m mBC treatment. ORSERDUTM (elacestrant). 2023 Available from: https://www.orserdu.com (Accessed on: 25 Oct 2023).
  137. Bihani T. Patel H.K. Arlt H. Tao N. Jiang H. Brown J.L. Purandare D.M. Hattersley G. Garner F. Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER+ breast cancer patient-derived xenograft models. Clin. Cancer Res. 2017 23 16 4793 4804 10.1158/1078‑0432.CCR‑16‑2561 28473534
    [Google Scholar]
  138. Jesduvroq (daprodustat) approved by US FDA for anaemia of chronic kidney disease in adults on dialysis. 2023 Available from: https://www.gsk.com/en-gb/media/press-releases/jesduvroq-daprodustat-approved-by-us-fda-for-anaemia-of-chronic-kidney-disease-in-adults-on-dialysis (Accessed on: 25 Oct 2023).
  139. Holdstock L. Cizman B. Meadowcroft A.M. Biswas N. Johnson B.M. Jones D. Kim S.G. Zeig S. Lepore J.J. Cobitz A.R. Daprodustat for anemia: A 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin. Kidney J. 2019 12 1 129 138 10.1093/ckj/sfy013 30746140
    [Google Scholar]
  140. Highlights of prescription information. JESDUVROQ (daprodustat) tablets, for oral use. 2023 Available from: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Jesduvroq/pdf/JESDUVROQ-PI-MG.PDF (Accessed on: 25 Oct 2023).
  141. Jesduvroq (daprodustat) approved by US FDA for anemia of chronic kidney disease in adults on dialysis. 2023 Available from: https://us.gsk.com/en-us/media/press-releases/jesduvroq-daprodustat-approved-by-us-fda-for-anemia-of-chronic-kidney-disease-in-adults-on-dialysis (Accessed on: 25 Oct 2023).
  142. A treatment option. JESDUVROQ (daprodustat) for HCPs. 2023 Available from: https://www.jesduvroqhcp.com (Accessed on: 25 Oct 2023).
  143. Chiesi Global Rare Diseases announces FDA approval of Lamzede® (velmanase alfa-tycv) for alpha-mannosidosis. 2023 Available from: https://www.chiesi.com/en/chiesi-global-rare-diseases-announces-fda-approval-of-lamzede-velmanase-alfa-tycv-for-alpha-mannosidosis (Accessed on: 25 Oct 2023).
  144. Lamzede® (velmanase alfa-tycv). For patients and caregivers. 2023 Available from: https://chiesi-lamzede-live.cphostaccess.com (Accessed on: 25 Oct 2023).
  145. Lamzede (velmanase alfa) dosing, indications, interactions, adverse effects, and more. 2023 Available from: https://reference.medscape.com/drug/lamzede-velmanase-alfa-4000324 (Accessed on: 25 Oct 2023).
  146. Velmanase alfa. 2023 Available from: https://go.drugbank.com/drugs/DB12374 (Accessed on: 25 Oct 2023).
  147. Lamzede (velmanase alfa-tycv) injection. 2023 Available from: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4840-lamzede-velmanase-alfa-tycv-injection (Accessed on: 25 Oct 2023).
  148. Lamzede. 2023 Available from: https://dss.mo.gov/mhd/cs/advisory/rdac/pdf/july-ndfb/lamzede-ndfb-final.pdf (Accessed on: 25 Oct 2023).
  149. Palaniswamy C. Selvaraj D.R. Palaniappan D. Dual angiotensin II and endothelin receptor antagonists. Am. J. Ther. 2011 18 3 e67 e70 10.1097/MJT.0b013e3181cb4031 20093924
    [Google Scholar]
  150. Cosgrove D. Gratton M.A. Madison J. Vosik D. Samuelson G. Meehan D. Delimont D. Phillips G. Smyth B. Pramparo T. Jarocki D. Nguyen M. Komers R. Jenkinson C. Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice. J. Pathol. 2023 260 3 353 364 10.1002/path.6087 37256677
    [Google Scholar]
  151. Phase 3 clinical trial of dual endothelin-angiotensin receptor antagonist sparsentan: Significant effect - Knowledge - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd. 2023 Available from: https://www.hsppharma.com/info/phase-3-clinical-trial-of-dual-endothelin-angi-62010707.html (Accessed on: 25 Oct 2023).
  152. Sorah S. Mechanism of action and potential for therapeutics from combining endothelin type A antagonists and angiotensin II type 1 receptor blockers. 2023 Available from: https://ckd-ce.com/foundations_deara2 (Accessed on: 25 Oct 2023).
  153. Dual endothelin angiotensin receptor antagonists (DEARAs): Drugs, side effects, interactions & list. 2023 Available from: https://www.rxlist.com/how_do_dearas_work/drug-class.htm (Accessed on: 25 Oct 2023).
  154. Dayalan Naidu S. Dinkova-Kostova A.T. Omaveloxolone (SkyclarysTM) for patients with friedreich’s ataxia. Trends Pharmacol. Sci. 2023 44 6 394 395 10.1016/j.tips.2023.03.005 37142519
    [Google Scholar]
  155. Shapiro L. Skyclarys (omaveloxolone) for Friedreich’s ataxia. 2023 Available from: https://friedreichsataxianews.com/friedreichs-ataxia-experimental-treatments/rta-408-omaveloxolone (Accessed on: 25 Oct 2023).
  156. Rare disease advisor. 2023 Available from: https://www.rarediseaseadvisor.com/therapies/skyclarys-omaveloxolone-rta-408 (Accessed on: 25 Oct 2023).
  157. Skyclarys (omaveloxolone). 2023 Available from: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4845-skyclarys-omaveloxolone (Accessed on: 25 Oct 2023).
  158. Highlights for prescribing information. SKYCLARYSTM (omaveloxolone) capsules, for oral use. 2023 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216718Orig1s000lbl.pdf (Accessed on: 25 Oct 2023).
  159. ZAVZPRETTM clinical pharmacology ([zavegepant] nasal spray). Pfizer medical Information-US. 2023 Available from: https://www.pfizermedicalinformation.com/en-us/node/1105061/pi_section/field_spl_clinical_pharmacology (Accessed on: 25 Oct 2023).
  160. Pfizer’s ZAVZPRETTM (zavegepant) migraine nasal spray receives FDA approval. 2023 Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-zavzprettm-zavegepant-migraine-nasal-spray (Accessed on: 25 Oct 2023).
  161. Zavegepant. 2023 Available from: https://en.wikipedia.org/w/index.php?title=Zavegepant&oldid=1172226743 (Accessed on: 25 Oct 2023).
  162. Zavzpret (zavegepant) nasal spray. 2023 Available from: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4847-zavzpret-zavegepant-nasal-spray (Accessed on: 25 Oct 2023).
  163. Zavzpret (zavegepant intranasal) dosing, indications, interactions, adverse effects, and more. 2023 Available from: https://reference.medscape.com/drug/zavzpret-zavegepant-intranasal-4000309 (Accessed on: 25 Oct 2023).
  164. Acadia Pharmaceuticals announces DAYBUETM (trofinetide) is now available for the treatment of Rett syndrome. 2023 Available from: https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-daybue-trofinetide-is-now-available-for-the-treatment-of-rett-syndrome (Accessed on: 25 Oct 2023).
  165. Acadia Pharmaceuticals announces U.S. FDA approval of DAYBUETM (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. 2023 Available from: https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-u-s-fda-approval-of-daybue-trofinetide-for-the-treatment-of-rett-syndrome-in-adult-and-pediatric-patients-two-years-of-age-and-older (Accessed on: 25 Oct 2023).
  166. FDA approves trofinetide, now Daybue, as 1st treatment for Rett. New Acadia therapy expected to be available in US by end of April. 2023 Available from: https://rettsyndromenews.com/news/fda-approves-trofinetide-now-daybue-first-rett-treatment-us (Accessed on: 25 Oct 2023).
  167. Anderson S.D. Brannan J.D. Long-acting beta 2-adrenoceptor agonists and exercise-induced asthma: Lessons to guide us in the future. Paediatr. Drugs 2004 6 3 161 175 10.2165/00148581‑200406030‑00003 15170363
    [Google Scholar]
  168. Hudu S.A. Elmigdadi F. Qtaitat A.A. Almehmadi M. Alsaiari A.A. Allahyani M. Aljuaid A. Salih M. Alghamdi A. Alrofaidi M.A. Abida Imran M. Abida, imran, m. trofinetide for rett syndrome: Highlights on the development and related inventions of the first USFDA-approved treatment for rare pediatric unmet medical need. J. Clin. Med. 2023 12 15 5114 10.3390/jcm12155114 37568516
    [Google Scholar]
  169. Gizurarson S. Methods and compositions for the delivery of a therapeutic agent. Patent US8217033B2, 2012
  170. Schwartz J.-C. Arrang J.-M. Garbarg M. Lecomte J.-M. Ligneau X. Schunack W.G. Stark H. Ganellin C.R. Leurquin F. Elz S. Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications. Patent US7169928B2, 2007
  171. Antle V. ulfoalkyl ether cyclodextrin compositions. Patent US7635773B2, 2009
  172. Kreutzer R. Limmer S. Limmer S. Hadwiger P. Compositions and methods for inhibiting expression of a target gene. Patent US8546143B2, 2013
  173. Vieira M.L. Huang A.B. Bhatt P.P. Formulations of viloxazine. Patent US9358204B2, 2016
  174. Wilton S.D. Fletcher S. Adams A. Meloni P. Antisense molecules and methods for treating pathologies. Patent US9228187B2, 2016
  175. Graupe M. Henri S.J. Link J.O. Rowe C.W. Saito R.D. Schroeder S.D. Stefanidis D. Tse W.C. Zhang J.R. Therapeutic compounds. Patent US10071985B2, 2018
  176. Chen Y. Cheng H. Li S. Wu Y. Feng Y. Lv B. Xu B. Seed B. Hadd M.J. Song Y. Du J. Wang C. Roberge J.Y. Benzylbenzene derivatives and methods of use. Patent US7838499B2, 2010
  177. Guisot N. Compounds useful as kinase inhibitors. Patent US1034278B2, 2019
  178. Hamaoka S. Kitazawa N. Nara K. Sasaki A. Kamada A. Okabe T. Selective estrogen receptor modulator. Patent US7612114B2, 2009
  179. Duffy K.J. Fitch D.M. Jin J. Liu R. Shaw A.N. Wiggall K. Prolyl hydroxylase inhibitors. Patent US8324208B2, 2012
  180. Zhang J. Dziewanowska Z.E. Belder R. Henderson I. Bogardus J.B. Zhang Z. Method for treating disorders associated with glomerular function. Patent US9993461B2, 2018
  181. Anderson E. Jiang X. Visnick M. Antioxidant inflammation modulators: Oleanolic acid derivatives with amino and other modifications at C-17. Patent US8124799B2, 2012
  182. Chaturvedula P.V. Chen L. Civiello R. Degnan A.P. Dubowchik G.M. Han X. Jiang X.J.J. Karageorge G.N. Luo G. Mcor J.E. Poindexter G. Tora G. Calcitonin gene related peptide receptor antagonists. Patent US7220862B2, 2007
  183. Glass L.I. Bickerdike M.J. Snape M.F. Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid. Patent US9212204B2, 2015
  184. Ezike T.C. Okpala U.S. Onoja U.L. Nwike C.P. Ezeako E.C. Okpara O.J. Okoroafor C.C. Eze S.C. Kalu O.L. Odoh E.C. Nwadike U.G. Ogbodo J.O. Umeh B.U. Ossai E.C. Nwanguma B.C. Advances in drug delivery systems, challenges and future directions. Heliyon 2023 9 6 e17488 10.1016/j.heliyon.2023.e17488 37416680
    [Google Scholar]
  185. Laffleur F. Keckeis V. WITHDRAWN: Advances in drug delivery systems: Work in progress still needed? Int. J. Pharm. X 2020 2 100050 10.1016/j.ijpx.2020.100050 32577616
    [Google Scholar]
  186. Choudhary A. Novel drug delivery system. Pharmaguideline. 2023 Available from: https://www.pharmaguideline.com/2021/06/novel-drug-delivery-system.html?m=1 (Accessed on: 25 Oct 2023).
  187. Patra J.K. Das G. Fraceto L.F. Campos E.V.R. Rodriguez-Torres M.P. Acosta-Torres L.S. Diaz-Torres L.A. Grillo R. Swamy M.K. Sharma S. Habtemariam S. Shin H.S. Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnology 2018 16 1 71 10.1186/s12951‑018‑0392‑8 30231877
    [Google Scholar]
  188. Mohammadi-Samani S. Ghasemiyeh P. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages. Res. Pharm. Sci. 2018 13 4 288 303 10.4103/1735‑5362.235156 30065762
    [Google Scholar]
  189. Pons-Faudoa F.P. Ballerini A. Sakamoto J. Grattoni A. Advanced implantable drug delivery technologies: Transforming the clinical landscape of therapeutics for chronic diseases. Biomed. Microdevices 2019 21 2 47 10.1007/s10544‑019‑0389‑6 31104136
    [Google Scholar]
  190. Kalaydina R.V. Bajwa K. Qorri B. DeCarlo A. Szewczuk M.R. Recent advances in “smart” delivery systems for extended drug release in cancer therapy. Int. J. Nanomedicine 2018 13 4727 4745 10.2147/IJN.S168053 30154657
    [Google Scholar]
  191. Melson E. Ashraf U. Papamargaritis D. Davies M.J. What is the pipeline for future medications for obesity? Int. J. Obes. 2024 24 01473 10.1038/s41366‑024‑01473‑y 38302593
    [Google Scholar]
/content/journals/cdd/10.2174/0115672018353367250317063449
Loading
Novel Drug Delivery Systems Approved by USFDA from 2019 to 2023: A Comprehensive Review
Bentham Science Publishers ; https://doi.org/10.2174/0115672018353367250317063449
/content/journals/cdd/10.2174/0115672018353367250317063449
/content/journals/cdd/10.2174/0115672018353367250317063449
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: USFDA ; marketed products ; novel drug delivery systems ; patents ; Antibody drug-conjugate ; block copolymer micelles

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test